26-A-10902-ACC A PHASE 1 DOSE-ESCALATION AND -EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED SRSD216 IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)